95 related articles for article (PubMed ID: 27036326)
1. Morphology and MMP-9, AR and IGFR-1 responses of the seminal vesicle in TRAMP mice model.
Dal Pozzo CF; Kido LA; Montico F; Gonçalves MP; Cagnon VH
Tissue Cell; 2016 Jun; 48(3):217-23. PubMed ID: 27036326
[TBL] [Abstract][Full Text] [Related]
2. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Yeh IT; Reddick RL; Kumar AP
Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
[TBL] [Abstract][Full Text] [Related]
3. P21 and P27 promote tumorigenesis and progression via cell cycle acceleration in seminal vesicles of TRAMP mice.
Li T; Wang F; Dang Y; Dong J; Zhang Y; Zhang C; Liu P; Gao Y; Wang X; Yang S; Lu S
Int J Biol Sci; 2019; 15(10):2198-2210. PubMed ID: 31592235
[TBL] [Abstract][Full Text] [Related]
4. Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.
Jachetti E; Rigoni A; Bongiovanni L; Arioli I; Botti L; Parenza M; Cancila V; Chiodoni C; Festinese F; Bellone M; Tardanico R; Tripodo C; Colombo MP
Mol Cancer Ther; 2017 Feb; 16(2):365-375. PubMed ID: 27980106
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model.
Tani Y; Suttie A; Flake GP; Nyska A; Maronpot RR
Vet Pathol; 2005 May; 42(3):306-14. PubMed ID: 15872376
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice.
Montico F; Kido LA; Hetzl AC; Lorencini RM; Cândido EM; Cagnon VH
Histochem Cell Biol; 2014 Sep; 142(3):269-84. PubMed ID: 24562790
[TBL] [Abstract][Full Text] [Related]
8. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
[TBL] [Abstract][Full Text] [Related]
9. Growth response and androgen receptor expression in seminal vesicles from aging transgenic mice expressing human or bovine growth hormone genes.
Prins GS; Cecim M; Birch L; Wagner TE; Bartke A
Endocrinology; 1992 Oct; 131(4):2016-23. PubMed ID: 1396345
[TBL] [Abstract][Full Text] [Related]
10. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
12. Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies.
Martiniello-Wilks R; Dane A; Mortensen E; Jeyakumar G; Wang XY; Russell PJ
Anticancer Res; 2003; 23(3B):2633-42. PubMed ID: 12894551
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
14. MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP).
Arbab AS; Shankar A; Varma NR; Deeb D; Gao X; Iskander AS; Janic B; Ali MM; Gautam SC
BMC Med Imaging; 2011 Dec; 11():21. PubMed ID: 22165848
[TBL] [Abstract][Full Text] [Related]
15. The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis.
Quick CM; Gokden N; Sangoi AR; Brooks JD; McKenney JK
Hum Pathol; 2010 Aug; 41(8):1145-9. PubMed ID: 20413145
[TBL] [Abstract][Full Text] [Related]
16. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
17. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
18. Genistein alters growth factor signaling in transgenic prostate model (TRAMP).
Wang J; Eltoum IE; Lamartiniere CA
Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738
[TBL] [Abstract][Full Text] [Related]
19. Mixed epithelial-stromal tumor (MEST) of seminal vesicle: a proposal for unified nomenclature.
Reikie BA; Yilmaz A; Medlicott S; Trpkov K
Adv Anat Pathol; 2015 Mar; 22(2):113-20. PubMed ID: 25664946
[TBL] [Abstract][Full Text] [Related]
20. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
